ExodusPoint Capital Management’s Verve Therapeutics VERV Stock Holding History

ExodusPoint Capital Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-22,227	Closed	-$108K	–	2097
2024 Q3	$108K	Buy	+22,227	New	+$129K	﹤0.01%	1509
2024 Q1	–	Sell	-24,036	Closed	-$335K	–	1987
2023 Q4	$335K	Sell	24,036 -208,584	-90%	-$2.59M	﹤0.01%	1148
2023 Q3	$3.08M	Buy	232,620 +42,549	+22%	+$685K	0.03%	524
2023 Q2	$3.56M	Sell	190,071 -73,549	-28%	-$1.22M	0.03%	576
2023 Q1	$3.8M	Buy	263,620 +196,276	+291%	+$3.84M	0.03%	620
2022 Q4	$1.3M	Buy	+67,344	New	+$1.78M	0.02%	838
2022 Q3	–	Sell	-114,117	Closed	-$1.74M	–	2331
2022 Q2	$1.74M	Buy	+114,117	New	+$1.77M	0.02%	843
2021 Q3	–	Sell	-5,345	Closed	-$322K	–	2671
2021 Q2	$322K	Buy	+5,345	New	+$222K	﹤0.01%	1698

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ExodusPoint Capital Management's VERV Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 22,227 shares — an estimated $108K sold.

ExodusPoint Capital Management first reported a position in VERV in Q2 2021 and held it in 8 quarters. The position peaked at $3.8M in Q1 2023. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

ExodusPoint Capital Management reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 22,227 Verve Therapeutics shares in Q4 2024, an estimated $108K.
ExodusPoint Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 8 quarters.
ExodusPoint Capital Management's Verve Therapeutics position peaked at $3.8M in Q1 2023.
166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.